Healthcare Intelligence
Cardiovascular Devices
Real-time intelligence, expert analysis, and verified research for the Cardiovascular Devices industry. Stay ahead in 3 minutes a day.
Stay ahead of Cardiovascular Devices in 3 minutes a day.
Expert-verified intelligence delivered to your inbox every morning.
Free forever. No spam. Unsubscribe anytime.
New Anti-Clotting Drug Asundexian Cuts Stroke Risk 26% Without Bleeding
Global OCEANIC-STROKE trial shows asundexian reduces recurrent stroke risk without increasing major bleeding in 12,327 patients.
Read full articleChina Develops Lab-Grown Heart Tissue as Pacemaker Alternative
Shanghai scientists create 3D sinoatrial node organoid that generates electrical impulses, potentially replacing electronic pacemakers.
Read full articleWegovy Linked to Rare Vision Loss Condition in FDA Safety Analysis
Study finds Wegovy has 75x higher odds of causing ischemic optic neuropathy compared to expected rates, raising safety concerns.
Read full articleEli Lilly's Retatrutide Shows 30% Weight Loss in Phase 3 Trial
Triple-action obesity drug achieves near bariatric surgery-level results with participants losing up to 85 pounds over 80 weeks.
Read full articleBiological Pacemakers Move Closer to Reality with Stem Cell Advances
Researchers engineer heart cells that generate spontaneous rhythmic impulses, potentially eliminating need for battery replacements.
Read full articleFactor XIa Inhibitor First to Complete Phase 3 Stroke Prevention Trial
Asundexian becomes first Factor XIa inhibitor to successfully complete Phase 3 trial, offering new approach to anti-clotting therapy.
Read full articleLab-Grown Heart Organoid Linked to Artificial Nerve Network
Chinese scientists connect sinoatrial node organoid to artificial cardiac plexus, recreating nervous system-heart communication.
Read full articleGLP-1 Drug Safety Concerns Rise as Prescriptions Expand Beyond Diabetes
As GLP-1 drugs gain popularity for weight loss and other conditions, new safety signals emerge requiring urgent investigation.
Read full articleNew Anti-Clotting Drug Asundexian Cuts Stroke Risk 26% Without Bleeding
Global OCEANIC-STROKE trial shows asundexian reduces recurrent stroke risk without increasing major bleeding in 12,327 patients.
Read full articleChina Develops Lab-Grown Heart Tissue as Pacemaker Alternative
Shanghai scientists create 3D sinoatrial node organoid that generates electrical impulses, potentially replacing electronic pacemakers.
Read full articleWegovy Linked to Rare Vision Loss Condition in FDA Safety Analysis
Study finds Wegovy has 75x higher odds of causing ischemic optic neuropathy compared to expected rates, raising safety concerns.
Read full articleEli Lilly's Retatrutide Shows 30% Weight Loss in Phase 3 Trial
Triple-action obesity drug achieves near bariatric surgery-level results with participants losing up to 85 pounds over 80 weeks.
Read full articleBiological Pacemakers Move Closer to Reality with Stem Cell Advances
Researchers engineer heart cells that generate spontaneous rhythmic impulses, potentially eliminating need for battery replacements.
Read full articleFactor XIa Inhibitor First to Complete Phase 3 Stroke Prevention Trial
Asundexian becomes first Factor XIa inhibitor to successfully complete Phase 3 trial, offering new approach to anti-clotting therapy.
Read full articleLab-Grown Heart Organoid Linked to Artificial Nerve Network
Chinese scientists connect sinoatrial node organoid to artificial cardiac plexus, recreating nervous system-heart communication.
Read full articleGLP-1 Drug Safety Concerns Rise as Prescriptions Expand Beyond Diabetes
As GLP-1 drugs gain popularity for weight loss and other conditions, new safety signals emerge requiring urgent investigation.
Read full articleStay ahead of Cardiovascular Devices in 3 minutes a day.
Live opportunity intelligence for your market, delivered to your inbox every morning. Read it over coffee.
Free forever. No spam. Unsubscribe anytime.